Article

Who is the ideal candidate to receive HIFU?

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Jennifer A. Linehan, MD, discusses patient selection for high-intensity focused ultrasound. Linehan is an associate professor of urology and urologic oncology at Saint John’s Cancer Institute in Santa Monica, California.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Related Content
      Conceptual image for viral ethiology of prostate cancer. 3D illustration showing Human Papilloma Viruses HPV infecting prostate gland which develops cancerous tumor | Image Credit: © Dr_Microbe - stock.adobe.com
      June 27th 2025

      Biden’s prostate cancer diagnosis underscores importance of screening, awareness

      Hannah Clarke
      The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      June 26th 2025

      177Lu-rhPSMA-10.1 injection shows positive radiation dosimetry results in mCRPC

      Hannah Clarke
      The results demonstrated a favorable ratio between radiation doses absorbed in the tumor vs the doses delivered to key healthy organs.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
      June 20th 2025

      FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

      Hannah Clarke
      The phase 1 study is set to begin later this year.
      CHMP recommends EU approval of darolutamide plus ADT in mHSPC
      June 20th 2025

      CHMP recommends EU approval of darolutamide plus ADT in mHSPC

      Hannah Clarke
      The approval is supported by data from the pivotal phase 3 ARANOTE trial.
      © 2025 MJH Life Sciences

      All rights reserved.